GeneDx Holdings (WGS) Total Liabilities (2020 - 2026)

GeneDx Holdings (WGS) has reported Total Liabilities for 7 consecutive years, with $252.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Liabilities rose 33.41% year-over-year to $252.2 million; the TTM figure through Mar 2026 stood at $252.2 million (up 33.41% YoY), while the FY2025 annual figure was $215.5 million, up 23.77% from the prior year.
• Total Liabilities climbed to $252.2 million in Q1 2026 per WGS's latest filing, from $215.5 million in the prior quarter.
• Across five years, Total Liabilities topped out at $296.0 million in Q2 2022 and bottomed at $163.0 million in Q3 2023.
• Historically, Total Liabilities has averaged $208.6 million across 5 years, with a median of $195.1 million in 2024.
• On a YoY basis, Total Liabilities climbed as much as 42.92% in 2022 and fell as far as 53.72% in 2022.
• GeneDx Holdings' Total Liabilities stood at $237.2 million in 2022, then declined by 19.6% to $190.7 million in 2023, then fell by 8.71% to $174.1 million in 2024, then gained by 23.77% to $215.5 million in 2025, then gained by 17.0% to $252.2 million in 2026.
• Business Quant data shows WGS's Total Liabilities at $252.2 million in Q1 2026, $215.5 million in Q4 2025, and $201.6 million in Q3 2025.